Allergan plc Company Profile (NYSE:AGN)

About Allergan plc (NYSE:AGN)

Allergan plc logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:AGN
  • CUSIP: 01849010
  • Web:
  • Market Cap: $75.29 billion
  • Outstanding Shares: 335,867,000
Average Prices:
  • 50 Day Moving Avg: $235.40
  • 200 Day Moving Avg: $223.25
  • 52 Week Range: $184.50 - $261.27
  • Trailing P/E Ratio: 6.99
  • Foreward P/E Ratio: 12.48
  • P/E Growth: 1.11
Sales & Book Value:
  • Annual Revenue: $14.74 billion
  • Price / Sales: 5.11
  • Book Value: $209.35 per share
  • Price / Book: 1.07
  • Dividend Yield: 1.3%
  • EBIDTA: $5.8 billion
  • Net Margins: 100.04%
  • Return on Equity: 7.21%
  • Return on Assets: 4.00%
  • Debt-to-Equity Ratio: 0.37%
  • Current Ratio: 3.95%
  • Quick Ratio: 3.86%
  • Average Volume: 2.66 million shs.
  • Beta: 1.07
  • Short Ratio: 2.69

Frequently Asked Questions for Allergan plc (NYSE:AGN)

What is Allergan plc's stock symbol?

Allergan plc trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan plc pay dividends? What is the dividend yield for Allergan plc?

Allergan plc announced a quarterly dividend on Friday, May 5th. Investors of record on Thursday, May 18th will be given a dividend of $0.70 per share on Thursday, June 15th. This represents a $2.80 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date of this dividend is Tuesday, May 16th. View Allergan plc's Dividend History.

How were Allergan plc's earnings last quarter?

Allergan plc (NYSE:AGN) released its quarterly earnings data on Tuesday, May, 9th. The company reported $3.35 EPS for the quarter, topping analysts' consensus estimates of $3.32 by $0.03. The business had revenue of $3.57 billion for the quarter, compared to analyst estimates of $3.53 billion. Allergan plc had a return on equity of 7.21% and a net margin of 100.04%. The firm's revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.04 EPS. View Allergan plc's Earnings History.

What guidance has Allergan plc issued on next quarter's earnings?

Allergan plc issued an update on its FY17 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of $15.85-16.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.01.

Where is Allergan plc's stock going? Where will Allergan plc's stock price be in 2017?

18 brokerages have issued 1 year price targets for Allergan plc's shares. Their predictions range from $205.00 to $300.00. On average, they expect Allergan plc's stock price to reach $267.50 in the next twelve months. View Analyst Ratings for Allergan plc.

What are analysts saying about Allergan plc stock?

Here are some recent quotes from research analysts about Allergan plc stock:

  • 1. Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)
  • 2. According to Zacks Investment Research, "Allergan is reshaping its portfolio through acquisitions/divestitures. Allergan has been pretty active on the acquisition front and made six new product acquisitions in the third quarter. With the Allergan, Inc. acquisition, the company finds itself among the top 10 pharmas worldwide based on sales. Moreover, with the closing of the Teva deal, the company’s restructured and simplified business is encouraging. As a result, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Biosimilars also represent significant opportunity. Also, Allergan’s shares outperformed the generic industry in past six months. However, while we remain optimistic about the company’s growth prospects, the company is facing generic threat for Namenda IR as well as patent challenges for some of the other products in its branded portfolio, which concerns us." (1/3/2017)

Who are some of Allergan plc's key competitors?

Who owns Allergan plc stock?

Allergan plc's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), State Street Corp (4.74%), Janus Capital Management LLC (1.13%), Bank of New York Mellon Corp (1.09%), Veritas Asset Management LLP (0.00%) and TIAA CREF Investment Management LLC (0.00%). Company insiders that own Allergan plc stock include Brent L Saunders, Maria Teresa Hilado, Nesli Basgoz and Paul Bisaro. View Institutional Ownership Trends for Allergan plc.

Who sold Allergan plc stock? Who is selling Allergan plc stock?

Allergan plc's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Paulson & CO. Inc., Macquarie Group Ltd., TCW Group Inc., TIAA CREF Investment Management LLC, Saba Capital Management L.P. and Bank of New York Mellon Corp. Company insiders that have sold Allergan plc stock in the last year include Nesli Basgoz and Paul Bisaro. View Insider Buying and Selling for Allergan plc.

Who bought Allergan plc stock? Who is buying Allergan plc stock?

Allergan plc's stock was purchased by a variety of institutional investors in the last quarter, including Veritas Asset Management LLP, Iridian Asset Management LLC CT, Renaissance Technologies LLC, Blue Ridge Capital L.L.C., First Manhattan Co., Canyon Capital Advisors LLC, Schroder Investment Management Group and Swiss National Bank. Company insiders that have bought Allergan plc stock in the last two years include Brent L Saunders, Maria Teresa Hilado and Paul Bisaro. View Insider Buying and Selling for Allergan plc.

How do I buy Allergan plc stock?

Shares of Allergan plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Allergan plc stock cost?

One share of Allergan plc stock can currently be purchased for approximately $224.16.

Analyst Ratings

Consensus Ratings for Allergan plc (NYSE:AGN) (?)
Ratings Breakdown: 5 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.72)
Consensus Price Target: $267.50 (19.33% upside)

Analysts' Ratings History for Allergan plc (NYSE:AGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017Goldman Sachs Group IncDowngradeBuy -> Neutral$262.00HighView Rating Details
5/10/2017Royal Bank of CanadaBoost Price TargetOutperform -> Outperform$279.00 -> $284.00HighView Rating Details
4/24/2017Citigroup IncBoost Price TargetBuy$261.00LowView Rating Details
3/28/2017Deutsche Bank AGBoost Price TargetBuy$262.00 -> $265.00LowView Rating Details
2/22/2017Piper Jaffray CompaniesSet Price TargetHold$205.00N/AView Rating Details
2/14/2017Credit Suisse Group AGReiterated RatingBuy$274.00N/AView Rating Details
2/9/2017Leerink SwannBoost Price TargetBuy$280.00N/AView Rating Details
2/7/2017MizuhoReiterated RatingBuy$273.00 -> $275.00N/AView Rating Details
12/25/2016Sanford C. BernsteinSet Price TargetBuy$275.00N/AView Rating Details
12/23/2016Bank of America CorpReiterated RatingBuy$280.00N/AView Rating Details
12/6/2016ArgusReiterated RatingBuy$340.00 -> $260.00N/AView Rating Details
12/5/2016JPMorgan Chase & Co.Set Price TargetBuy$300.00N/AView Rating Details
11/21/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
11/3/2016Morgan StanleyLower Price TargetOverweight$300.00 -> $274.00N/AView Rating Details
10/31/2016Barclays PLCReiterated RatingEqual Weight$250.00N/AView Rating Details
9/21/2016Cantor FitzgeraldDowngradeBuy -> HoldN/AView Rating Details
6/10/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
5/24/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/7/2016Raymond James Financial, Inc.Lower Price TargetOutperform$317.00 -> $275.00N/AView Rating Details
4/7/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
4/7/2016Susquehanna Bancshares IncDowngradePositive -> Neutral$345.00 -> $275.00N/AView Rating Details
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00N/AView Rating Details
6/20/2015BMO Capital MarketsSet Price TargetBuy$378.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Allergan plc (NYSE:AGN)
Earnings by Quarter for Allergan plc (NYSE:AGN)
Earnings History by Quarter for Allergan plc (NYSE:AGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017$3.32$3.35$3.53 billion$3.57 billionViewListenView Earnings Details
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.57$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.20$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.41$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
11/5/2014Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details
8/5/2014Q314$1.76$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
4/30/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Allergan plc (NYSE:AGN)
2017 EPS Consensus Estimate: $16.04
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$3.33$3.55$3.44
Q2 20172$3.85$4.07$3.96
Q3 20172$4.09$4.16$4.13
Q4 20172$4.35$4.67$4.51
(Data provided by Zacks Investment Research)


Current Dividend Information for Allergan plc (NYSE:AGN)
Next Dividend:6/15/2017
Annual Dividend:$2.80
Dividend Yield:1.25%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:7.48% (Trailing 12 Months of Earnings)
17.39% (Based on This Year's Estimates)
15.59% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Allergan plc (NYSE:AGN)

Dividend History by Quarter for Allergan plc (NYSE:AGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Allergan plc (NYSE:AGN)
Insider Ownership Percentage: 0.27%
Institutional Ownership Percentage: 86.40%
Insider Trades by Quarter for Allergan plc (NYSE:AGN)
Institutional Ownership by Quarter for Allergan plc (NYSE:AGN)
Insider Trades by Quarter for Allergan plc (NYSE:AGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017Nesli BasgozDirectorSell1,889$220.45$416,430.05View SEC Filing  
3/2/2017Paul BisaroDirectorSell70,000$246.68$17,267,600.00View SEC Filing  
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.08View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.77View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.90View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.00View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.00View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.00View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.00View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.00View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.00View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.74View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.00View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.00View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.00View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.00View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.00View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.00View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Allergan plc (NYSE:AGN)
Latest Headlines for Allergan plc (NYSE:AGN)
DateHeadline logoAllergan Announces Early Tender Results and Upsizing of Tender Offers by Certain Subsidiaries - May 24 at 3:24 PM logoShark Bites: Focus on the 'Little Picture' - May 24 at 3:24 PM logoTracking Wallace Weitz's Weitz Investment Management Portfolio - Q1 2017 Update - May 24 at 6:55 AM logoAllergan Announces Pricing of Public Offering of Senior Notes to Refinance Existing Debt - May 24 at 6:55 AM logoKristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch RHOFADE™ (Oxymetazoline HCL) Cream, 1% - May 24 at 6:55 AM logoAllergan Funding SCS -- Moody's assigns Baa3 to Allergan's euro notes; stable outlook - May 23 at 3:27 PM logoHas Allergan's Pullback Run Its Course? - May 23 at 3:27 PM logoAllergan launches offering of senior unsecured notes to rollover existing debt - May 23 at 7:29 AM logoAllergan Announces Commencement of Proposed Public Offering of Senior Notes to Refinance Existing Debt - May 23 at 6:43 AM logoThese Big Drug Stocks May Cure the Trump Blues - May 23 at 6:43 AM logoNesli Basgoz Sells 1,889 Shares of Allergan plc (AGN) Stock - May 22 at 7:46 PM logoValeant Pharmaceuticals: Intrigued…Really? - May 19 at 3:24 PM logoAllergan's Irritable Bowel Drug Viberzi Approved in Canada - May 17 at 12:37 PM logoAllergan Becomes Oversold (AGN) - May 16 at 3:24 PM logoVIBERZI™ Now Approved in Canada for patients with irritable bowel syndrome with diarrhea (IBS-D) - May 16 at 3:24 PM logoCramer: Carl Icahn Was Right to Sell Apple at $95 - May 16 at 3:24 PM logoIs Editas Facing a New Reality in CRISPR Land? - May 16 at 3:24 PM logoSeveral top fund managers trim Allergan stakes in first quarter - May 16 at 6:44 AM logoAllergan plc. (AGN) Ex-Dividend Date Scheduled for May 16, 2017 - Nasdaq - May 15 at 3:24 PM logoETFs with exposure to Allergan Plc : May 15, 2017 - May 15 at 3:24 PM logoAllergan: What's Going On? - Seeking Alpha - May 15 at 8:01 AM logoStill an Allergan Fan; Oil Vey!: Doug Kass' Views - May 15 at 8:00 AM logoRoyal Bank of Canada Raises Allergan plc (AGN) Price Target to $284.00 - May 14 at 8:22 PM logoGoldman Sachs Group Inc Downgrades Allergan plc (AGN) to Neutral - May 14 at 6:28 PM logoAllergan's Q1: A Review - Seeking Alpha - May 12 at 3:55 PM logoPharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study - May 12 at 3:54 PM logoAllergan Plc :AGN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 - May 12 at 3:54 PM logoCourt Battle May Be Responsible For Spiking Drugmaker's Stock - May 12 at 3:54 PM logoBehind Allergan’s US General Medicines Segment in 1Q17 - May 11 at 3:40 PM logoToday's Research Reports on Stocks to Watch: Allergan and Celgene - May 11 at 3:40 PM logoWhat Happened to Allergan’s International Segment in 1Q17? - May 11 at 3:40 PM logoFinal Trades: Valeant, Allergan and more - May 11 at 3:40 PM logoUnderstanding Allergan’s Valuation after the 1Q17 Results - May 11 at 3:40 PM logoAllergan plc (AGN) Forecasted to Post FY2017 Earnings of $16.05 Per Share - May 11 at 11:42 AM logoAllergan plc Target of Unusually Large Options Trading (AGN) - May 11 at 7:12 AM logoAllergan: Does The Pipeline Trump The Buyback Signal? - Seeking Alpha - May 10 at 8:34 PM logoAllergan Announces Proposed Public Offering of Senior Notes to Refinance Existing Debt - May 10 at 9:30 AM logoAllergan Announces Tender Offers by Certain Subsidiaries - May 10 at 9:30 AM logoEdited Transcript of AGN earnings conference call or presentation 9-May-17 12:30pm GMT - May 10 at 9:30 AM logoAllergan Plc breached its 50 day moving average in a Bearish Manner : AGN-US : May 10, 2017 - May 10 at 9:30 AM logoAllergan posts loss as it writes down Teva holdings - May 9 at 8:24 PM logoAllergan (AGN) Beats Q1 Earnings Estimates, Ups 2017 View - May 9 at 8:24 PM logoAllergan Says It Continues to Look at Stepping-Stone Deals - May 9 at 8:24 PM logoCramer Remix: Where the money leaving retail stocks could be headed - May 9 at 8:24 PM logoIronwood Pharma perks up 8% on potential Allergan interest - May 9 at 4:41 PM logoAllergan Mandatory Convertible Preferred Shares, Series A Goes Ex-Dividend Soon - Nasdaq - May 9 at 3:23 PM logoAllergan Plc (AGN) Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - May 9 at 3:23 PM logoAllergan plc (AGN) Issues Earnings Results, Beats Estimates By $0.04 EPS - May 9 at 9:56 AM logoAllergan Raises 2017 Guidance To Reflect Contribution From ZELTIQ - Quick Facts - May 9 at 9:25 AM logoAllergan tops earnings estimates on strength of Botox, eye care products - May 9 at 9:25 AM



Allergan plc (AGN) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff